Hemostatic alterations in COVID-19
Flora Peyvandi, Andrea Artoni, Cristina Novembrino, Stefano Aliberti, Mauro Panigada, Marco Boscarino, Roberta Gualtierotti, Federica Rossi, Roberta Palla, Ida Martinelli, Giacomo Grasselli, Francesco Blasi, Armando Tripodi
Abstract
Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 1,2 that, first identified in China, has spread globally. A coagulopathy is common, particularly in patients admitted to intensive care units (ICU). 3 Although controversial, 4-6 high rates of venous thromboembolism (VTE) have also been reported. The International Society on Thrombosis and Haemostasis (ISTH) released a statement suggesting prophylactic low molecular weight heparin (LMWH). 8 However, the optimal strategy for prophylaxis remains controversial, 9 owing to limited knowledge on how COVID-19 affects hemostasis.